EOLS:NASDAQEvolus, Inc. Common Stock Analysis

Evolus, Inc. (EOLS) is trading at $6.73, comfortably above its 20‑day ($6.48), 50‑day ($5.73) and 200‑day ($5.92) moving averages, suggesting short‑term momentum despite a neutral overall trend. The RSI of 60 signals the stock is not yet overbought, while the MACD histogram is slightly negative, hinting at a modest bearish tilt. The price sits near the $5.95 support level with $6.94 resistance, and volume remains stable amid a high 30‑day volatility of over 60%, compounded by a beta of 1.21 and an “Extreme Greed” market sentiment. On the fundamentals side, revenue grew 6.7% YoY to $302 M with a strong 66% gross margin, yet operating and net margins are negative (‑9.4% and ‑14.4%), cash flow is negative and the balance sheet shows $165 M of debt against a negative book value per share. Forward EPS of $0.27 translates to a forward P/E of ~25, aligning with the industry average, and analysts’ median target of $14 implies over 100% upside.
The upcoming Q1 earnings release and management’s participation in the Jefferies Global Healthcare Conference provide a near‑term catalyst, while the strong “strong_buy” consensus (6 analysts) underscores optimism. However, the company’s negative equity, high leverage, and ongoing cash‑burn raise medium‑ to long‑term concerns, making the stock a high‑risk, high‑reward proposition.